Resonance Health Ltd · ASX:RHT
Resonance Health — Shareholder Meeting (September 2006)
7 slides from Resonance Health's shareholder meeting presentation, Sep 29, 2006
Slide 1: Extraordinary General Meeting
Resonance: ACN 006 762 492 Extraordinary General Meeting 29th September 2006
Slide 2: Chairman's Presentation
Resonance. Chairman’s Presentation
Slide 3: Background
Background Resonance: LIMay 06 re-constituted Board conduct in- depth review of FerriScan® performance and RHT financials >FerriScan® sales continue to lag projections > Unlikely to have sufficient cash to last to end of 2006 LICEO steps down
Slide 4: Background: Board actions taken
Backg round Resonance LIBoard actions taken > Reduced burn rate (complete May /June) > Increased FerriScan® pricing to major customer through Jan 07 (complete August 06) >» Rights issue to existing shareholders (complete September 06) - $3,087,989 raised > Recruit CEO (complete September 06)
Slide 5: RHT CEO
RHT CEO Resonance. (Edward D. Dooling, Jr, B.Sc. UExtensive US experience marketing, sales, consolidating operations in pathology labs and introducing innovative technologies >» Diagnostic Pathology Services: Executive VP Sales > Asterand: Chief Operating Officer > AmeriPath: Vice President and Gene
Slide 6: Strategy
Strategy Resonance’ LPathology lab roll-up Linvest in business and technology innovations that are synergistic or complimentary with the path lab network >FerriScan® & path labs are complimentary - common sales call points
Slide 7: Looking Forward
Looking Forward Resonance: O Revise FerriScan® commercialization plan LJExecute pathology lab acquisition/roll-up >» Supported by Queensland Biotechnology Fund (QBF) > QBF supported rights issue (now own ~ 18.9% of RHT) >» Montgomery Pacific continues evaluation of pathology labs UO Continue FibroSc
Resonance Health — Shareholder Meeting (September 2006) on 6ix